Literature DB >> 25609505

[Melanoma: introduction and special demands on radiology].

M Schiller1, J C Hassel.   

Abstract

CLINICAL ISSUE: The incidence of melanoma has rapidly increased in the last decades. Most relevant for patient prognosis is the tumor thickness, hence an early diagnosis is crucial. STANDARD TREATMENT: The basis of treatment is at the primary tumor stage and excision of regional metastases with curative intention. TREATMENT INNOVATIONS: Targeted therapies, such as BRAF and MEK inhibitors have the advantage of a rapid response even in highly advanced stages of the disease. DIAGNOSTIC WORK-UP: For routine diagnostics ultrasound, computed tomography (CT), fluorodeoxyglucose positron emission tomography CT (FDG-PET/CT) and magnetic resonance imaging (MRI) are used. PERFORMANCE AND ACHIEVEMENTS: In the treatment of distant metastases new treatment options are available which more than doubled patient survival rates. Especially immune therapies with immune checkpoint blockers, such as ipilimumab or PD-1 antibodies can lead to long-term survival of patients. In contrast to chemotherapy these new substances have characteristics which make new demands on radiologists related to the possibility of pseudoprogression in immune therapies, which make it necessary to use other response criteria. In addition, autoimmune phenomena, such as a sarcoid-like reactions may mimic new metastases and should be included in the differential diagnosis. BRAF inhibitors may lead to cystic conversions of metastases which again require an evaluation beyond the response evaluation criteria in solid tumors (RECIST), e.g. with the adapted Choi criteria. PRACTICAL RECOMMENDATIONS: Close interdisciplinary communication, functional imaging methods and adapted response criteria, such as the immune-related response criteria will optimize radiological evaluations of melanoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25609505     DOI: 10.1007/s00117-014-2758-8

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  23 in total

1.  Systematic skin cancer screening in Northern Germany.

Authors:  Eckhard W Breitbart; Annika Waldmann; Sandra Nolte; Marcus Capellaro; Ruediger Greinert; Beate Volkmer; Alexander Katalinic
Journal:  J Am Acad Dermatol       Date:  2011-11-08       Impact factor: 11.527

2.  Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission.

Authors:  Wouter V Vogel; Aurelie Guislain; Pia Kvistborg; Ton N M Schumacher; John B A G Haanen; Christian U Blank
Journal:  J Clin Oncol       Date:  2011-11-28       Impact factor: 44.544

3.  KIT as a therapeutic target in metastatic melanoma.

Authors:  Richard D Carvajal; Cristina R Antonescu; Jedd D Wolchok; Paul B Chapman; Ruth-Ann Roman; Jerrold Teitcher; Katherine S Panageas; Klaus J Busam; Bartosz Chmielowski; Jose Lutzky; Anna C Pavlick; Anne Fusco; Lauren Cane; Naoko Takebe; Swapna Vemula; Nancy Bouvier; Boris C Bastian; Gary K Schwartz
Journal:  JAMA       Date:  2011-06-08       Impact factor: 56.272

4.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Authors:  C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

5.  Associated factors in the prevalence of more than 50 common melanocytic nevi, atypical melanocytic nevi, and actinic lentigines: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society.

Authors:  C Garbe; P Büttner; J Weiss; H P Soyer; U Stocker; S Krüger; M Roser; J Weckbecker; R Panizzon; F Bahmer
Journal:  J Invest Dermatol       Date:  1994-05       Impact factor: 8.551

6.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

7.  Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.

Authors:  Antoni Ribas; Begoña Comin-Anduix; James S Economou; Timothy R Donahue; Pilar de la Rocha; Lilah F Morris; Jason Jalil; Vivian B Dissette; Itsushi Peter Shintaku; John A Glaspy; Jesus Gomez-Navarro; Alistair J Cochran
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

Review 8.  CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Authors:  Patrick A Ott; F Stephen Hodi; Caroline Robert
Journal:  Clin Cancer Res       Date:  2013-10-01       Impact factor: 12.531

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

10.  Does biopsy type influence survival in clinical stage I cutaneous melanoma?

Authors:  J S Lederman; A J Sober
Journal:  J Am Acad Dermatol       Date:  1985-12       Impact factor: 11.527

View more
  1 in total

1.  Immune checkpoint inhibitors and response analysis: a tough challenge. A case report.

Authors:  Alessandra Bearz; Tiziana Perin; Luca Cancian; Eleonora Berto; Ivana Sartor; Umberto Tirelli
Journal:  BMC Res Notes       Date:  2016-07-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.